CRISPR Therapeutics AG (CRSP)

Broker Ratings

⚠️ No article content returned.

Share on:

Latest Company News

Solid state design drives weight, cost and efficiency gains

Solid state design offers Ilika a compelling path to value through weight savings, pack simplification and improved EV performance.

Metals strength and yield curve shift could bolster UK equities

Strong metals and a shifting yield curve could support the FTSE 100’s upward trend into 2026.

Tekmar secures strategic offshore wind contract, reinforcing market position

Tekmar wins €8m offshore wind contract, boosting visibility on 2026–27 revenue.

Drax builds local links through seasonal initiative at Cruachan Visitor Centre

Drax hosted a fundraising event at its Cruachan Visitor Centre, supporting Oban RNLI and reinforcing community ties near a key energy site.

Rethinking risk at the edge of a new global order

Ruffer warns that ignoring politics is no longer an option for investors in a shifting global regime.

Time Finance adds credit firepower with new structured lending lead

Time Finance appoints Geoff Worrall to lead structured credit, strengthening its asset finance capabilities and focus on tailored lending.

    Search

    Search